



Kubota Pharmaceutical Holdings Co., Ltd. to Present at the Refractive Surgery Update Seminar 2023 in Kyoto

Seattle (July 20, 2023) — Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo: 4596) (“Kubota Pharma” or the “Company”) announced today announced that Dr. Ryo Kubota, Chairman, President and CEO, will speak on Kubota Glass technology at the Refractive Surgery Update Seminar 2023 in Kyoto, Japan.

This educational seminar is organized by the Refractive Kansai Research Association (Nichigan Continuing Education Accreditation Project No. 22081) and will be held on July 29, 2023, at Kyoto Sangyo Kaikan Hall. Dr. Kubota will present the effect of myopia suppression in children using an ophthalmic AR device that reproduces outdoor environments based on the theory of correcting peripheral hyperopia entitled “What is Kubota Glass?”

The Refractive Kansai Research Association was founded in early 2001 and has organized the Refractive Surgery Update Seminar since 2016. Academic analysis of refractive treatment in myopia will be discussed by many ophthalmologists, medical professionals, and related companies.

Dr. Kubota stated, “I am very pleased to have the opportunity to speak at the conference, as I did last year. I look forward to discussing with many people, including medical professionals, who are researching ways to control the progression of myopia and its treatment, so that we can move forward with our future research.”

About Kubota Glass™ Technology

Kubota Glasses technology works to reduce the increase in axial length associated with myopia by projecting myopically-defocused virtual images generated using micro-LEDS on the peripheral visual field to actively stimulate the retina. Passive stimulation using myopic defocus is already in use in the U.S. with a contact lens, “MiSight® 1 day” by CooperVision, which is U.S. Food and Drug Administration (FDA) approved to slow the progression of myopia. This product, which uses multifocal contact lens technology, passively stimulates the entire peripheral retina with light myopically defocused by the non-central power of the contact lens. Kubota Glasses technology leverages nanotechnology in its electronic glasses-based device and seeks to reduce the progression of myopia by actively stimulating the retina for shorter periods while maintaining high-quality central vision and not affecting daily activities.

About Kubota Pharmaceutical Holdings Co., Ltd.

Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) is committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Kubota Pharmaceutical group’s pipeline includes a wearable device for myopia control using Kubota Glass technology and a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients. <https://www.kubotaholdings.co.jp/en/>

Cautionary Statements

Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include statements regarding our expectations related to our development plans and ability to successfully develop and commercialize our product candidates and the potential efficacy, future development plans and commercial potential of our product candidates. These statements are based on current assumptions that involve risks, uncertainties and other factors that could cause the actual results, events or developments to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: our investigational product candidates may not demonstrate the expected safety and efficacy; our pre-clinical development efforts may not yield additional product candidates; any of our or our collaborators' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; our clinical trials could be delayed; new developments in the intensely competitive ophthalmic pharmaceutical market may require changes in our clinical trial plans or limit the potential benefits of our investigational product candidates; the impact of expanded product development and clinical activities on operating expenses; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. For a detailed discussion of the foregoing risks and other risk factors, please refer to our filings with the Securities and Exchange Commission, which are available on Kubota Pharmaceutical Holdings (Kubota Vision's parent company) investor relations website (<https://www.kubotaholdings.co.jp/en/ir/>) and on the SEC's website (<http://www.sec.gov>).

“Kubota Vision,” the Kubota Vision logo and “Kubota” are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.

Media and Investor Relations Contact:

Press and Media Inquiries

Phone: +81-3-6550-8928

Email: pr@kubotaholdings.co.jp

###